IlluMyFi - ENHERTU ® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Burnit

LOGIN REGISTER

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

uk.investing.com 06-04-2024 01:58 0.5 Minutes reading

#Meta

Info

Sentiment

0

Bearish/Bullish

50

Related news

Russia's Aeroflot diverts Tehran-bound flight, pos...

13.04.24 11:45

by uk.investing.com

Russia's Aeroflot diverts Tehran-bound flight, postpones others

#Russia

Sentiment

0

Bearish/Bullish

50

Germany's Lindner plays down coalition breakup fea...

Germany's Lindner plays down coalition breakup fears,...

Earnings call: CBAT Energy reports strong growth a...

#Energy #Art Energy

Earnings call: CBAT Energy reports strong growth and...

Earnings call: Mondee boasts strong 2023 results

Earnings call: Mondee boasts strong 2023 results

Earnings call: Coherus BioSciences reports strong...

#Science

Earnings call: Coherus BioSciences reports strong Q4

Exclusive-Google steps up Microsoft criticism, war...

Exclusive-Google steps up Microsoft criticism, warns of...

Judge Calls Out Ivanka Trump In New York Civil Fra...

Judge Calls Out Ivanka Trump In New York Civil...

SAP board chair designate to resign, Ala-Pietila n...

SAP board chair designate to resign, Ala-Pietila nominated...

HF Foods Appoints Felix Lin as President of the Co...

HF Foods Appoints Felix Lin as President of the...